top of page
Wissenschaftler mit Mikroskop

Clinical trials with new drugs

APEX

Patient target group

Study details

Name of study

Sponsor

Clinical Center

HARBOR

Patient target group

Study details

Name of Study

Sponsor

Clinical Center

 

 

PIONEER

Target of patients

Study details

Name of Study

Sponsor

Clinical Center

SUMMIT

Target of patients

Study details

Name of Study​

Sponsor

Clinical Center

Patient target group

Advanced systemic mastocytosis

Study details

Study to test the efficacy and safety of the tyrosine kinase inhibitor bezuclastinib in patients with advanced systemic mastocytosis

Name of study

A Phase 2, Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis (APEX)

Sponsor

Cogent

Clinical Center

University Hospital Basel, current status: Patients wanted (recruitement open)

 

Patient target group

Indolent sysstemic mastocytosis

Study details

Study to evaluate the efficacy and safety of the tyrosine kinase inhibitor elenestinib (compared to placebo) in patients with indolent systemic mastocytosis

Name of Study

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-26 in Indolent Systemic Mastocytosis (HARBOR)

Sponsor

Blueprint

Clinical Center

University Hospital Basel, current status: No new patients can be included in the study until 2024 (recruitment paused)

Luzerner Kantonsspital, current status: no patients can be included in the study until 2024 (recruitment paused)

Patient target group

Indolent and smoldering systemic mastocytosis

Study details

Study to test the efficacy and safety of the tyrosine kinase inhibitor avapritinib in patients with indolent systemic mastocytosis

Name of Study

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy (PIONEER)

Sponsor

Blueprint

Clinical Center

University Hospital Basel, current status: no more patients needed for the study (recruitment completed)

..

Patient target group

Indolent systemic mastocytosis

Name of Study

Study to test the efficacy and safety of the tyrosine kinase inhibitor bezuclastinib (compared to placebo) in patients with indolent systemic mastocytosis

Study details

A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with Nonadvanced Systemic Mastocytosis (SUMMIT)

Sponsor

Cogent

Clinical Center

University Hospital Basel, current status: Patients wanted (recruitment open)

Registries / Observational Studies
ECNM Registry
Patient target group
Study details
Name of study
Sponsor
Clinical Centers

Patient target group

All forms of mastocytosis

Study details

International registry for patients with mastocytosis

Name of Study

Data Registry of the European Competence Network on Mastocytosis (ECNM)

Sponsor

Prof. Dr. Wolfang Sperr and Prof. Dr. Peter Valent, Medical University of Vienna

Clinical Center

Kantonsspital Aarau, current status: patients wanted (recruitment open)

University Hospital Basel, current status: patients wanted (recruitment open)

Luzerner Kantonsspital, current status: patients wanted (recruitment open)

Biobank
Biobank Allergy and Immunity, University Hospital Basel
Patient target troup

Details
Sponsor
Status

Patient target group

All forms of mastocytosis

Study details

Collection of biological material (blood, tissue samples) of patients with mastocytosis to investigate basic disease mechanisms

Sponsor

Prof. Dr. Karin Hartmann, University Hospital Basel and University of Basel

Status

Patients wanted (recruitment open)

bottom of page